Inovio Pharmaceuticals Doubles in April, Will It Go Higher?

Inovio Pharmaceuticals

Rich first profiled Inovio Pharmaceuticals Inc. (NASDAQ:INO) just before it exploded in early March. The pharma stock went from $4.39 to $14.09 over the course of just one week, though it didn’t stay there for long. INO shares hovered between $7.00 and $8.00 for the rest of the month as the company slowly advanced its potential COVID-19 vaccine candidate.

This month, however, things really started to take off. INO entered April at $7.70 and has consistently gained value since then. Today, it’s trading at $14.83 and continues to trend upward.

“Inovio is secretly killing it,” says Rich, in regards to the stock’s subtle but consistent gains. “I think Inovio is a pharma stock is one that everybody should be looking at. It might be too late to get in now, but they’ve been doing extremely well, and could go higher.”

Enter Your E-mail Address To Subscribe

* indicates required

Inovio Pharmaceuticals CEO Says Vaccine Could Be Ready in 12-18 Months

The company’s potential COVID-19 vaccine, INO-4800, recently entered phase 1 clinical trials. This will involve up to 40 healthy adults, who will each receive two doses of the vaccine four weeks apart. The goals are to test the vaccine’s safety, as well as its ability to trigger an immune response in the body. Inovio expects data from this trial by late summer.

Following that, CEO Joseph Kim recently stated that it’s possible to meet the timeline of 12 to 18 months for a novel coronavirus (COVID-19) vaccine. This timeline was originally suggested by White House Coronavirus Task Force leader Dr. Anthony Fauci.

It’s worth noting, though, that INO remains a risky play. Though its vaccine candidate is making progress, it’s racing some major players like Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE), and could fall behind them. In addition, the company has no approved products on the market.

Inovio Pharmaceuticals has put all their eggs into the COVID-19 basket. Will it pay off?

INO Receives Consensus “Buy” Rating from Analysts

Analysts at HC Wainwright, Maxim Group, and Stifel Nicolaus have all awarded INO a “buy” rating in the last two months. While some analysts are beginning to return “hold” recommendations, the overall outlook for this pharma stock remains bullish.

What do you think? Is Inovio Pharmaceuticals at a ceiling, or could it continue to go higher? Let us know your thoughts!

Featured image: DepositPhotos © 18percentgrey

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Bitrex Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.